Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Finished Goods (2020 - 2025)

Historic Finished Goods for Pharma (IGC) over the last 6 years, with Q3 2025 value amounting to $212000.0.

  • Pharma's Finished Goods fell 4752.48% to $212000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $212000.0, marking a year-over-year decrease of 4752.48%. This contributed to the annual value of $256000.0 for FY2025, which is 4195.01% down from last year.
  • As of Q3 2025, Pharma's Finished Goods stood at $212000.0, which was down 4752.48% from $271000.0 recorded in Q2 2025.
  • Pharma's 5-year Finished Goods high stood at $1.0 million for Q3 2021, and its period low was $212000.0 during Q3 2025.
  • Its 5-year average for Finished Goods is $591631.6, with a median of $533000.0 in 2023.
  • As far as peak fluctuations go, Pharma's Finished Goods soared by 22295.08% in 2021, and later crashed by 4752.48% in 2025.
  • Over the past 5 years, Pharma's Finished Goods (Quarter) stood at $889000.0 in 2021, then fell by 20.58% to $706000.0 in 2022, then fell by 27.62% to $511000.0 in 2023, then dropped by 28.77% to $364000.0 in 2024, then tumbled by 41.76% to $212000.0 in 2025.
  • Its Finished Goods stands at $212000.0 for Q3 2025, versus $271000.0 for Q2 2025 and $256000.0 for Q1 2025.